Author of

• 36546

  +

  P85 - Targeted Therapy - Clinically Focused - MET (ID 262)

  • Event: WCLC 2020
  • Type: Posters
  • Track: Targeted Therapy - Clinically Focused
  • Presentations: 1
  • Moderators:
  • Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall

  • 36549

    +

    P85.03 - PD-L1 Expression and Efficacy of Immunotherapy in Japanese Patients with NSCLC Harboring MET Exon 14 Skipping Mutation. (ID 1667)

    00:00 - 00:00  |  Presenting Author(s): Yasuhiro Kato
    • Abstract
    • Slides

    Introduction
    

    MET exon 14 skipping mutation is an oncogenic driver of non-small-cell lung cancer (NSCLC). The effectiveness of MET inhibitors in NSCLC harboring MET exon 14 skipping mutation was observed in several previous prospective trials. In contrast, few studies reported programmed cell death ligand 1 (PD-L1) expression and the role of immunotherapies in MET exon 14 skipping mutation patients.

    Methods
    

    Medical charts of patients diagnosed with NSCLC harboring MET exon 14 skipping mutation from April 2016 to October 2019 in Saitama Cancer Center, Japan, were evaluated. Met exon 14 skipping mutation was analyzed using RT-PCR of the tumor tissue. Next-generation sequencing was performed on positive RT-PCR samples for confirmation. PD-L1 analysis was assessed through immunohistochemistry using 22C3 pharm Dx assay or 28-8 pharm Dx assay.

    Results
    

    A total of 1954 patients were screened and 67 patients (3.4%) with NSCLC harboring MET exon 14 skipping mutation were identified. The median age was 73 years. Patients who were male and former or current smokers were 41 (61.2%) and 35 (52.2%), respectively. NSCLC patients were classified as adenocarcinoma, 57 (85.0%); squamous, 5 (7.5%); adeno-squamous, 4 (6.0%); and pleomorphic, 1 (1.5%). PD-L1 expression was assessed in 23 samples. The PD-L1 expressions of 0%, 1%–49%, and ≥50% were 1 (4.3%), 6 (30.4%), and 16 (69.6%) respectively. Seven patients received immune-check point inhibitor (ICI) monotherapy. The objective response rate was 42.9% (3/7 95% CI, 10.0%–81.6%). Three patients had response to immunotherapies for >1 year. Contrarily, early disease progression was observed in all patients showing poor results within two months after ICI initiation. Eight patients were treated with MET inhibitor; however, no patient received ICI before or after MET inhibitor treatment.

    Conclusion
    

    In total, 70% of NSCLC with MET exon 14 skipping mutation had PD-L1 >50% and ICI monotherapy showed good efficacy in Japanese patients.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.